Trends in cardiovascular risk factors among patients with coronary heart disease: Results from the EUROASPIRE I, II, and III surveys in the Münster region;Trends kardiovaskulärer Risikofaktoren bei Patienten mit koronarer Herzkrankheit: Ergebnisse der EUROASPIRE I, II und III Surveys in der Region Münster

Deutsches Arzteblatt International

Volumn 109, Issue 17, 2012, Pages 303-309

  Prugger, Christof ^a,e   Heidrich, Jan ^a,f   Wellmann, Jürgen ^a   Dittrich, Ralf ^b   Brand, Stefan Martin ^a   Telgmann, Ralph ^a   Breithardt, Günter ^b   Reinecke, Holger ^b   Scheld, Hans ^b   Kleine Katthöfer, Peter ^c   Heuschmann, Peter U ^d   Keil, Ulrich ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c St Franziskus Hospital   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; EUROPE; GERMANY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PREVALENCE; SMOKING;

EID: 84903362784     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0303     Document Type: Article

References (25)

1. Chambless L, Keil U, Dobson A, et al.: Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. Circulation 1997; 96: 3849-59.
2. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Critchley JA, Capewell S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290: 86-97.
5. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85.
6. Taylor R, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K: Exer-cise-based rehabilitation for patients with coronary heart disease: Systematic Review and Meta-analysis of Randomized Controlled T rials. Am J Med 2004; 116: 682-92.
7. Graham I, Atar D, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(suppl 2): S1-113.
8. EUROASPIRE Study Group: EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart dis-ease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-82.
9. EUROASPIRE Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
10. EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention through Intervention to Reduce Events. Lancet 2001; 357: 995-1001.
11. Enbergs A, Liese A, Heimbach M, et al.: Evaluation of secondary prevention of coronary heart disease. Results of the EUROASPIRE study in the Münster region. Z Kardiol 1997; 86: 284-91.
12. Heidrich J, Liese AD, Kalic M, et al.: Secondary prevention of coronary heart disease. Results from EUROASPIRE I and II in the region of Munster, Germany. Dtsch Med Wochenschr 2002; 127: 667-72.
13. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-37.
14. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
15. Wu P, Wilson K, Dimoulas P, Mills EJ: Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
16. Lancaster T, Stead LF: Individual behavioural counselling for smok-ing cessation. Cochrane Database of Syst Rev 2005; CD001292.
17. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
18. Malmberg K, Yusuf S, Gerstein HC, et al.: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014-9.
19. Prugger C, Wellmann J, Heidrich J, Brand-Herrmann SM, Keil U: Cardiovascular risk factors and mortality in patients with coronary heart disease. Eur J Epidemiol 2008: 23: 731-7.
20. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
21. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
22. Klein S, Burke LE, Bray GA, et al.: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67.
23. Lenfant C: Shattuck lecture-clinical research to clinical practice-lost in translation? N Engl J Med 2003; 349: 868-74.
24. Heidrich J, Behrens T, Raspe F, Keil U: Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physi-cian survey in Germany. Eur J Cardiovasc Prev Rehabil 2005; 12: 521-9.
25. Hobbs FD, Erhardt L: Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596-604.